Nipro

Venari Medical Limited, founded in 2018 and based in Galway, Ireland, develops innovative medical devices aimed at treating chronic venous diseases (CVD). The company's flagship product, BioVena, employs the body's natural healing processes to provide a more effective and less invasive treatment option for conditions such as varicose veins and venous ulcers. Venari Medical seeks to address the significant gap in treatment, as only a small fraction of the 120 million individuals suffering from venous disease in the US and EU receive adequate care. Their technology not only offers a safer alternative to existing methods but also targets the underserved population of venous ulcer patients who currently rely on ineffective compression bandaging. By widening the indications for superficial venous ablation, Venari Medical aims to reduce the annual costs associated with venous ulcers, which total approximately $33 billion for insurers in these regions. The company's commitment to patient-centered solutions positions it to disrupt traditional treatment practices that have seen limited innovation in recent years.

TC BioPharm’s mission is to develop and commercialise innovative cell-based products to treat disease, improving patient health and Quality of Life. TC BioPharm is a clinical development company with a cell-based product pipeline capable of treating a variety of disorders including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell®, in renal cell cancinoma, non-small cell lung cancer and melanoma patients.

Infraredx, Inc. is a cardiovascular imaging medical device company focused on diagnosing and treating coronary artery diseases. Based in Burlington, Massachusetts, the company specializes in near-infrared spectroscopy (NIRS) technology, offering products such as the dual-modality NIRS-intravascular ultrasound (IVUS) True Vessel Characterization Imaging System, which identifies and characterizes lipid core coronary plaques. Other key products include the Makoto intravascular imaging system, the Dualpro catheter that combines IVUS and NIRS capabilities, and optical catheters that provide high-resolution images of plaque structures. Infraredx serves hospital sites primarily in the United States and Europe, and it operates as a subsidiary of Goodman USA, Inc. after being founded in 1998 and rebranding from InfraReDx, Inc. in 2012.

Infraredx, Inc. is a cardiovascular imaging medical device company focused on diagnosing and treating coronary artery diseases. Based in Burlington, Massachusetts, the company specializes in near-infrared spectroscopy (NIRS) technology, offering products such as the dual-modality NIRS-intravascular ultrasound (IVUS) True Vessel Characterization Imaging System, which identifies and characterizes lipid core coronary plaques. Other key products include the Makoto intravascular imaging system, the Dualpro catheter that combines IVUS and NIRS capabilities, and optical catheters that provide high-resolution images of plaque structures. Infraredx serves hospital sites primarily in the United States and Europe, and it operates as a subsidiary of Goodman USA, Inc. after being founded in 1998 and rebranding from InfraReDx, Inc. in 2012.

Home Diagnostics is a developer, manufacturer and marketer of blood glucose monitoring systems and disposable supplies for diabetics. Our blood glucose monitoring systems offer diabetics performance and features that are comparable to or better than our competitors products, in most cases at a substantially lower price.

Reprocell is a Research support business